Leila DARDAEI ALGHALANDIS,Jeffrey Adam ENGELMAN,Huaixiang HAO,Matthew J. LAMARCHE,Fang LI,Hui-Qin WANG
申请号：
US16475982
公开号：
US20190343836A1
申请日:
2018.01.08
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration； the uses of such combination in the treatment of proliferative diseases； and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
